Precision Medicine for Obesity

Abstract

Obesity is a multifactorial disease with a variable and underwhelming weight loss response to current treatment approaches. Precision medicine proposes a new paradigm to improve disease classification based on the premise of human heterogeneity, with the ultimate goal of maximizing treatment effectiveness, tolerability, and safety. Recent advances in high-throughput biochemical assays have contributed to the partial characterization of obesity's pathophysiology, as well as to the understanding of the role that intrinsic and environmental factors, and their interaction, play in its development and progression. These data have led to the development of biological markers that either are being or will be incorporated into strategies to develop personalized lines of treatment for obesity. There are currently many ongoing initiatives aimed at this; however, much needs to be resolved before precision obesity medicine becomes common practice. This review aims to provide a perspective on the currently available data of high-throughput technologies to treat obesity.

Keywords

phenotypes - ADOPT - genetics - microbiome

Disclosures

A.A. is a stockholder in Gila Therapeutics, Phenomix Sciences; he serves as a consultant for Rhythm Pharmaceuticals and General Mills.

Publikationsverlauf

Eingereicht: 04. Dezember 2020

Angenommen: 31. März 2021

Artikel online veröffentlicht:
17. Mai 2021

• References

• 1 Afshin A, Forouzanfar MH, Reitsma MB. et al; GBD 2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med 2017; 377 (01) 13-27
• 2 Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009; 9: 88
• 3 Nyberg ST, Batty GD, Pentti J. et al. Obesity and loss of disease-free years owing to major non-communicable diseases: a multicohort study. Lancet Public Health 2018; 3 (10) e490-e497
• 4 Waters H, Graf M. America's Obesity Crisis: The Health and Economic Costs of Excess Weight. The Milken Institute; ; October 26, 2018
• 5 Ward ZJ, Bleich SN, Cradock AL. et al. Projected U.S. state-level prevalence of adult obesity and severe obesity. N Engl J Med 2019; 381 (25) 2440-2450
• 6 Jensen MD, Ryan DH, Apovian CM. et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Obesity Society. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 2014; 129 (25, Suppl 2): S102-S138
• 7 Fitzpatrick SL, Wischenka D, Appelhans BM. et al; Society of Behavioral Medicine. An evidence-based guide for obesity treatment in primary care. Am J Med 2016; 129 (01) 115.e1-115.e7
• 8 Acosta A, Streett S, Kroh MD. et al. White Paper AGA: POWER - Practice Guide on Obesity and Weight Management, Education, and Resources. Clin Gastroenterol Hepatol 2017; 15 (05) 631-649.e10
• 9 Deurenberg P, Weststrate JA, Seidell JC. Body mass index as a measure of body fatness: age- and sex-specific prediction formulas. Br J Nutr 1991; 65 (02) 105-114
• 10 WHO. Obesity: Preventing and Managing the Global Epidemic. World Health Organization; 2000
• 11 Ross R, Neeland IJ, Yamashita S. et al. Waist circumference as a vital sign in clinical practice: a consensus statement from the IAS and ICCR Working Group on Visceral Obesity. Nat Rev Endocrinol 2020; 16 (03) 177-189
• 12 Sharma AM, Kushner RF. A proposed clinical staging system for obesity. Int J Obes 2009; 33 (03) 289-295
• 13 Padwal RS, Pajewski NM, Allison DB, Sharma AM. Using the Edmonton obesity staging system to predict mortality in a population-representative cohort of people with overweight and obesity. CMAJ 2011; 183 (14) E1059-E1066
• 14 Garvey WT, Mechanick JI, Brett EM. et al; Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract 2016; 22 (Suppl. 03) 1-203
• 15 Knowler WC, Barrett-Connor E, Fowler SE. et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346 (06) 393-403
• 16 Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study. Obesity (Silver Spring) 2014; 22 (01) 5-13
• 17 Sacks FM, Bray GA, Carey VJ. et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med 2009; 360 (09) 859-873
• 18 McMillan-Price J, Petocz P, Atkinson F. et al. Comparison of 4 diets of varying glycemic load on weight loss and cardiovascular risk reduction in overweight and obese young adults: a randomized controlled trial. Arch Intern Med 2006; 166 (14) 1466-1475
• 19 Das SK, Gilhooly CH, Golden JK. et al. Long-term effects of 2 energy-restricted diets differing in glycemic load on dietary adherence, body composition, and metabolism in CALERIE: a 1-y randomized controlled trial. Am J Clin Nutr 2007; 85 (04) 1023-1030
• 20 Slentz CA, Duscha BD, Johnson JL. et al. Effects of the amount of exercise on body weight, body composition, and measures of central obesity: STRRIDE--a randomized controlled study. Arch Intern Med 2004; 164 (01) 31-39
• 21 Apovian CM, Aronne LJ, Bessesen DH. et al; Endocrine Society. Pharmacological management of obesity: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2015; 100 (02) 342-362
• 22 Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2014; 311 (01) 74-86
• 23 Dong Z, Xu L, Liu H, Lv Y, Zheng Q, Li L. Comparative efficacy of five long-term weight loss drugs: quantitative information for medication guidelines. Obes Rev 2017; 18 (12) 1377-1385
• 24 Fujioka K, O’Neil PM, Davies M. et al. Early weight loss with Liraglutide 3.0 mg predicts 1-year weight loss and is associated with improvements in clinical markers. Obesity (Silver Spring) 2016; 24 (11) 2278-2288
• 25 Fujioka K, Plodkowski R, O'Neil PM, Gilder K, Walsh B, Greenway FL. The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy. Int J Obes 2016; 40 (09) 1369-1375
• 26 Abu Dayyeh BK, Kumar N, Edmundowicz SA. et al; ASGE Bariatric Endoscopy Task Force and ASGE Technology Committee. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc 2015; 82 (03) 425-38.e5
• 27 Buchwald H, Estok R, Fahrbach K. et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009; 122 (03) 248-256.e5
• 28 Chang SH, Stoll CR, Song J, Varela JE, Eagon CJ, Colditz GA. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA Surg 2014; 149 (03) 275-287
• 29 Christou NV, Look D, Maclean LD. Weight gain after short- and long-limb gastric bypass in patients followed for longer than 10 years. Ann Surg 2006; 244 (05) 734-740
• 30 Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med 2013; 273 (03) 219-234
• 31 Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015; 372 (09) 793-795
• 32 Gameiro GR, Sinkunas V, Liguori GR, Auler-Júnior JOC. Precision medicine: changing the way we think about healthcare. Clinics (São Paulo) 2018; 73: e723
• 33 Beckmann JS, Lew D. Reconciling evidence-based medicine and precision medicine in the era of big data: challenges and opportunities. Genome Med 2016; 8 (01) 134
• 34 Hudson K, Lifton R, Patrick-Lake B. The Precision Medicine Initiative Cohort Program—Building a Research Foundation for 21st Century Medicine. Precision Medicine Initiative (PMI) Working Group Report to the Advisory Committee to the Director. 2015
• 35 MacLean PS, Rothman AJ, Nicastro HL. et al. The Accumulating Data to Optimally Predict Obesity Treatment (ADOPT) Core Measures Project: rationale and approach. Obesity (Silver Spring) 2018; 26 (Suppl. 02) S6-S15
• 36 Chen R, Mias GI, Li-Pook-Than J. et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 2012; 148 (06) 1293-1307
• 37 Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol 2017; 18 (01) 83
• 38 Aleksandrova K, Egea Rodrigues C, Floegel A, Ahrens W. Omics biomarkers in obesity: novel etiological insights and targets for precision prevention. Curr Obes Rep 2020; 9 (03) 219-230
• 39 Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372 (6505): 425-432
• 40 Naggert J, Harris T, North M. The genetics of obesity. Curr Opin Genet Dev 1997; 7 (03) 398-404
• 41 Chen D, Garg A. Monogenic disorders of obesity and body fat distribution. J Lipid Res 1999; 40 (10) 1735-1746
• 42 Kaur Y, de Souza RJ, Gibson WT, Meyre D. A systematic review of genetic syndromes with obesity. Obes Rev 2017; 18 (06) 603-634
• 43 Schousboe K, Visscher PM, Erbas B. et al. Twin study of genetic and environmental influences on adult body size, shape, and composition. Int J Obes Relat Metab Disord 2004; 28 (01) 39-48
• 44 Farooqi IS, O'Rahilly S. Genetic factors in human obesity. Obes Rev 2007; 8 (Suppl. 01) 37-40
• 45 Qi L, Kang K, Zhang C. et al. Fat mass-and obesity-associated (FTO) gene variant is associated with obesity: longitudinal analyses in two cohort studies and functional test. Diabetes 2008; 57 (11) 3145-3151
• 46 Diels S, Vanden Berghe W, Van Hul W. Insights into the multifactorial causation of obesity by integrated genetic and epigenetic analysis. Obes Rev 2020; 21 (07) e13019
• 47 Wray NR, Goddard ME, Visscher PM. Prediction of individual genetic risk to disease from genome-wide association studies. Genome Res 2007; 17 (10) 1520-1528
• 48 Brunkwall L, Chen Y, Hindy G. et al. Sugar-sweetened beverage consumption and genetic predisposition to obesity in 2 Swedish cohorts. Am J Clin Nutr 2016; 104 (03) 809-815
• 49 Qi Q, Chu AY, Kang JH. et al. Fried food consumption, genetic risk, and body mass index: gene-diet interaction analysis in three US cohort studies. BMJ 2014; 348: g1610
• 50 Ahmad S, Rukh G, Varga TV. et al; InterAct Consortium, DIRECT Consortium. Gene × physical activity interactions in obesity: combined analysis of 111,421 individuals of European ancestry. PLoS Genet 2013; 9 (07) e1003607
• 51 Celis-Morales C, Lyall DM, Guo Y. et al. Sleep characteristics modify the association of genetic predisposition with obesity and anthropometric measurements in 119,679 UK Biobank participants. Am J Clin Nutr 2017; 105 (04) 980-990
• 52 Milagro FI, Mansego ML, De Miguel C, Martínez JA. Dietary factors, epigenetic modifications and obesity outcomes: progresses and perspectives. Mol Aspects Med 2013; 34 (04) 782-812
• 53 Rohde K, Keller M, la Cour Poulsen L, Blüher M, Kovacs P, Böttcher Y. Genetics and epigenetics in obesity. Metabolism 2019; 92: 37-50
• 54 Bell CG. The epigenomic analysis of human obesity. Obesity (Silver Spring) 2017; 25 (09) 1471-1481
• 55 Wahl S, Drong A, Lehne B. et al. Epigenome-wide association study of body mass index, and the adverse outcomes of adiposity. Nature 2017; 541 (7635): 81-86
• 56 Dick KJ, Nelson CP, Tsaprouni L. et al. DNA methylation and body-mass index: a genome-wide analysis. Lancet 2014; 383 (9933): 1990-1998
• 57 Barres R, Kirchner H, Rasmussen M. et al. Weight loss after gastric bypass surgery in human obesity remodels promoter methylation. Cell Rep 2013; 3 (04) 1020-1027
• 58 Rönn T, Volkov P, Davegårdh C. et al. A six months exercise intervention influences the genome-wide DNA methylation pattern in human adipose tissue. PLoS Genet 2013; 9 (06) e1003572
• 59 Milagro FI, Campión J, Cordero P. et al. A dual epigenomic approach for the search of obesity biomarkers: DNA methylation in relation to diet-induced weight loss. FASEB J 2011; 25 (04) 1378-1389
• 60 Cordero P, Campion J, Milagro FI. et al. Leptin and TNF-alpha promoter methylation levels measured by MSP could predict the response to a low-calorie diet. J Physiol Biochem 2011; 67 (03) 463-470
• 61 Nicoletti CF, Nonino CB, de Oliveira BAP. et al. DNA methylation and hydroxymethylation levels in relation to two weight loss strategies: energy-restricted diet or bariatric surgery. Obes Surg 2016; 26 (03) 603-611
• 62 Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 2009; 10 (01) 57-63
• 63 Amri EZ, Scheideler M. Small non coding RNAs in adipocyte biology and obesity. Mol Cell Endocrinol 2017; 456: 87-94
• 64 Ortiz-Dosal A, Rodil-García P, Salazar-Olivo LA. Circulating microRNAs in human obesity: a systematic review. Biomarkers 2019; 24 (06) 499-509
• 65 Deutsch A, Feng D, Pessin JE, Shinoda K. The impact of single-cell genomics on adipose tissue research. Int J Mol Sci 2020; 21 (13) 4773
• 66 González-Plaza JJ, Gutiérrez-Repiso C, García-Serrano S. et al. Effect of Roux-en-Y gastric bypass-induced weight loss on the transcriptomic profiling of subcutaneous adipose tissue. Surg Obes Relat Dis 2016; 12 (02) 257-263
• 67 Armenise C, Lefebvre G, Carayol J. et al. Transcriptome profiling from adipose tissue during a low-calorie diet reveals predictors of weight and glycemic outcomes in obese, nondiabetic subjects. Am J Clin Nutr 2017; 106 (03) 736-746
• 68 Holmes E, Wilson ID, Nicholson JK. Metabolic phenotyping in health and disease. Cell 2008; 134 (05) 714-717
• 69 Rangel-Huerta OD, Pastor-Villaescusa B, Gil A. Are we close to defining a metabolomic signature of human obesity? A systematic review of metabolomics studies. Metabolomics 2019; 15 (06) 93-93
• 70 Baker II PR, Boyle KE, Koves TR. et al. Metabolomic analysis reveals altered skeletal muscle amino acid and fatty acid handling in obese humans. Obesity (Silver Spring) 2015; 23 (05) 981-988
• 71 Gao X, Zhang W, Wang Y. et al. Serum metabolic biomarkers distinguish metabolically healthy peripherally obese from unhealthy centrally obese individuals. Nutr Metab (Lond) 2016; 13 (01) 33
• 72 Cirulli ET, Guo L, Leon Swisher C. et al. Profound perturbation of the metabolome in obesity is associated with health risk. Cell Metab 2019; 29 (02) 488-500.e2
• 73 Badoud F, Lam KP, Perreault M, Zulyniak MA, Britz-McKibbin P, Mutch DM. Metabolomics reveals metabolically healthy and unhealthy obese individuals differ in their response to a caloric challenge. PLoS One 2015; 10 (08) e0134613
• 74 Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project. Nature 2007; 449 (7164): 804-810
• 75 Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol 2020; 19 (01) 55-71
• 76 Turnbaugh PJ, Hamady M, Yatsunenko T. et al. A core gut microbiome in obese and lean twins. Nature 2009; 457 (7228): 480-484
• 77 Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A 2011; 108 (Suppl. 01) 4554-4561
• 78 Santacruz A, Marcos A, Wärnberg J. et al; EVASYON Study Group. Interplay between weight loss and gut microbiota composition in overweight adolescents. Obesity (Silver Spring) 2009; 17 (10) 1906-1915
• 79 Ding S, Chi MM, Scull BP. et al. High-fat diet: bacteria interactions promote intestinal inflammation which precedes and correlates with obesity and insulin resistance in mouse. PLoS One 2010; 5 (08) e12191
• 80 Vaughn AC, Cooper EM, DiLorenzo PM. et al. Energy-dense diet triggers changes in gut microbiota, reorganization of gut-brain vagal communication and increases body fat accumulation. Acta Neurobiol Exp (Warsz) 2017; 77 (01) 18-30
• 81 Sayin SI, Wahlström A, Felin J. et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 2013; 17 (02) 225-235
• 82 Calderon G, McRae A, Rievaj J. et al. Ileo-colonic delivery of conjugated bile acids improves glucose homeostasis via colonic GLP-1-producing enteroendocrine cells in human obesity and diabetes. EBioMedicine 2020; 55: 102759
• 83 Tims S, Derom C, Jonkers DM. et al. Microbiota conservation and BMI signatures in adult monozygotic twins. ISME J 2013; 7 (04) 707-717
• 84 Liu R, Hong J, Xu X. et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention. Nat Med 2017; 23 (07) 859-868
• 85 Vrieze A, Van Nood E, Holleman F. et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012; 143 (04) 913-6.e7
• 86 Palleja A, Kashani A, Allin KH. et al. Roux-en-Y gastric bypass surgery of morbidly obese patients induces swift and persistent changes of the individual gut microbiota. Genome Med 2016; 8 (01) 67
• 87 Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature 2015; 526 (7573): 343-350
• 88 Li QS, Lenhard JM, Zhan Y. et al. A candidate-gene association study of topiramate-induced weight loss in obese patients with and without type 2 diabetes mellitus. Pharmacogenet Genomics 2016; 26 (02) 53-65
• 89 de Luis DA, Diaz Soto G, Izaola O, Romero E. Evaluation of weight loss and metabolic changes in diabetic patients treated with liraglutide, effect of RS 6923761 gene variant of glucagon-like peptide 1 receptor. J Diabetes Complications 2015; 29 (04) 595-598
• 90 Chedid V, Vijayvargiya P, Carlson P. et al. Allelic variant in the glucagon-like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: a pilot pharmacogenetics study. Neurogastroenterol Motil 2018; 30 (07) e13313
• 91 O'Connor A, Swick AG. Interface between pharmacotherapy and genes in human obesity. Hum Hered 2013; 75 (2-4): 116-126
• 92 Zhang JP, Lencz T, Zhang RX. et al. Pharmacogenetic associations of antipsychotic drug-related weight gain: a systematic review and meta-analysis. Schizophr Bull 2016; 42 (06) 1418-1437
• 93 Fenech M, El-Sohemy A, Cahill L. et al. Nutrigenetics and nutrigenomics: viewpoints on the current status and applications in nutrition research and practice. J Nutrigenet Nutrigenomics 2011; 4 (02) 69-89
• 94 Ramos-Lopez O, Milagro FI, Allayee H. et al. Guide for current nutrigenetic, nutrigenomic, and nutriepigenetic approaches for precision nutrition involving the prevention and management of chronic diseases associated with obesity. J Nutrigenet Nutrigenomics 2017; 10 (1-2): 43-62
• 95 Heianza Y, Qi L. Gene-diet interaction and precision nutrition in obesity. Int J Mol Sci 2017; 18 (04) 787
• 96 Farooqi IS, Jebb SA, Langmack G. et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999; 341 (12) 879-884
• 97 Clément K, van den Akker E, Argente J. et al; Setmelanotide POMC and LEPR Phase 3 Trial Investigators. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol 2020; 8 (12) 960-970
• 98 Collet TH, Dubern B, Mokrosinski J. et al. Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency. Mol Metab 2017; 6 (10) 1321-1329
• 99 Celis-Morales C, Marsaux CF, Livingstone KM. et al. Can genetic-based advice help you lose weight? Findings from the Food4Me European randomized controlled trial. Am J Clin Nutr 2017; 105 (05) 1204-1213
• 100 Frankwich KA, Egnatios J, Kenyon ML. et al. Differences in weight loss between persons on standard balanced vs nutrigenetic diets in a randomized controlled trial. Clin Gastroenterol Hepatol 2015; 13 (09) 1625-1632.e1
• 101 Gardner CD, Trepanowski JF, Del Gobbo LC. et al. Effect of low-fat vs low-carbohydrate diet on 12-month weight loss in overweight adults and the association with genotype pattern or insulin secretion: the DIETFITS Randomized Clinical Trial. JAMA 2018; 319 (07) 667-679
• 102 Horne JR, Gilliland JA, O'Connor CP, Seabrook JA, Madill J. Change in weight, BMI, and body composition in a population-based intervention versus genetic-based intervention: the NOW Trial. Obesity (Silver Spring) 2020; 28 (08) 1419-1427
• 103 Kranzler HR, Feinn R, Gelernter J, Pond T, Covault J. Topiramate's reduction of body mass index in heavy drinkers: lack of moderation by a GRIK1 polymorphism. Exp Clin Psychopharmacol 2014; 22 (05) 419-423
• 104 Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444 (7122): 1027-1031
• 105 Zeevi D, Korem T, Zmora N. et al. Personalized nutrition by prediction of glycemic responses. Cell 2015; 163 (05) 1079-1094
• 106 Kolodziejczyk AA, Zheng D, Elinav E. Diet-microbiota interactions and personalized nutrition. Nat Rev Microbiol 2019; 17 (12) 742-753
• 107 Duncan SH, Belenguer A, Holtrop G, Johnstone AM, Flint HJ, Lobley GE. Reduced dietary intake of carbohydrates by obese subjects results in decreased concentrations of butyrate and butyrate-producing bacteria in feces. Appl Environ Microbiol 2007; 73 (04) 1073-1078
• 108 Cani PD, Lecourt E, Dewulf EM. et al. Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal. Am J Clin Nutr 2009; 90 (05) 1236-1243
• 109 Cani PD, Joly E, Horsmans Y, Delzenne NM. Oligofructose promotes satiety in healthy human: a pilot study. Eur J Clin Nutr 2006; 60 (05) 567-572
• 110 Nicolucci AC, Hume MP, Martínez I, Mayengbam S, Walter J, Reimer RA. Prebiotics reduce body fat and alter intestinal microbiota in children who are overweight or with obesity. Gastroenterology 2017; 153 (03) 711-722
• 111 FAO, WHO. Probiotics in Food: Health and Nutritional Properties and Guidelines for Evaluation. FAO; 2006
• 112 Michael DR, Jack AA, Masetti G. et al. A randomised controlled study shows supplementation of overweight and obese adults with lactobacilli and bifidobacteria reduces bodyweight and improves well-being. Sci Rep 2020; 10 (01) 4183
• 113 Smits LP, Bouter KE, de Vos WM, Borody TJ, Nieuwdorp M. Therapeutic potential of fecal microbiota transplantation. Gastroenterology 2013; 145 (05) 946-953
• 114 Kootte RS, Levin E, Salojärvi J. et al. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. Cell Metab 2017; 26 (04) 611-619.e6
• 115 Lee P, Yacyshyn BR, Yacyshyn MB. Gut microbiota and obesity: an opportunity to alter obesity through faecal microbiota transplant (FMT). Diabetes Obes Metab 2019; 21 (03) 479-490
• 116 Huang YT, Maccani JZJ, Hawley NL, Wing RR, Kelsey KT, McCaffery JM. Epigenetic patterns in successful weight loss maintainers: a pilot study. Int J Obes 2015; 39 (05) 865-868
• 117 Benton MC, Johnstone A, Eccles D. et al. An analysis of DNA methylation in human adipose tissue reveals differential modification of obesity genes before and after gastric bypass and weight loss. Genome Biol 2015; 16 (01) 8
• 118 Kwon Y, Jang M, Lee Y, Ha J, Park S. Amino acid metabolites and slow weight loss in the early postoperative period after sleeve gastrectomy. J Clin Med 2020; 9 (08) E2348
• 119 Rice JP, Saccone NL, Rasmussen E. Definition of the phenotype. Adv Genet 2001; 42: 69-76
• 120 Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012; 18 (05) 716-725
• 121 Camilleri M. Peripheral mechanisms in appetite regulation. Gastroenterology 2015; 148 (06) 1219-1233
• 122 Camilleri M, Acosta A. Gastrointestinal traits: individualizing therapy for obesity with drugs and devices. Gastrointest Endosc 2016; 83 (01) 48-56
• 123 Acosta A, Camilleri M, Shin A. et al. Quantitative gastrointestinal and psychological traits associated with obesity and response to weight-loss therapy. Gastroenterology 2015; 148 (03) 537-546.e4
• 124 Pajot G, Camilleri M, Calderon G. et al. Association between gastrointestinal phenotypes and weight gain in younger adults: a prospective 4-year cohort study. Int J Obes 2020; 44 (12) 2472-2478
• 125 Delgado-Aros S, Kim DY, Burton DD. et al. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol 2002; 282 (03) G424-G431
• 126 Halawi H, Khemani D, Eckert D. et al. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. Lancet Gastroenterol Hepatol 2017; 2 (12) 890-899
• 127 Hjerpsted JB, Flint A, Brooks A, Axelsen MB, Kvist T, Blundell J. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab 2018; 20 (03) 610-619
• 128 Acosta A, Camilleri M, Burton D. et al. Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study. Physiol Rep 2015; 3 (11) e12610
• 129 Lopez-Nava G, Jaruvongvanich V, Storm AC. et al. Personalization of endoscopic bariatric and metabolic therapies based on physiology: a prospective feasibility study with a single fluid-filled intragastric balloon. Obes Surg 2020; 30 (09) 3347-3353